Skip to main content
OpenTrials
Completed

NCT Number: NCT00798512

Diffusion Weighted-MRI Based Evaluation of the Effectiveness of Endovascular Clamping During Carotid Artery Stenting With the Mo.Ma Device.

The purpose of this study is to detect new ischemic lesions after carotid artery stenting (with the Cristallo Ideale stent), in patients with high grade carotid artery stenosis, by diffusion-weighted magnetic resonance imaging (DW-MRI), using the endovascular proximal flow blockage (Mo.Ma device) for cerebral protection.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CardioVascular Center Frankfurt, Sankt Katharinen, Frankfurt, Germany

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ≥ 18 years old;
  • Eligibility for carotid artery revascularization;
  • A significant stenosis in symptomatic patients with ≥ 50% Diameter Stenosis (%DS) or asymptomatic ≥ 80 %DS as defined by angiography.

Symptomatic is defined as a carotid artery stenosis associated with ipsilateral TIA, amaurosis fugax, ischemic stroke or retinal infarction within 6 months prior to enrollment.

  • Suitable clinical conditions to perform DW-MRI.
  • Written informed consent as approved by the Ethics Committee of the respective clinical site.

Exclusion criteria

  • Female with childbearing potential without a negative pregnancy test.
  • Life-expectancy less than 6 months.
  • Underlying disease of the carotid artery other than atherosclerosis (e.g. vasculitis, traumatic dissection, fibromuscular dysplasia).
  • Prior stenting in the target vessel;
  • Patients with chronic or re-current atrial fibrillation.
  • Patient has had a Myocardial Infarction within 72 hours prior to the procedure.
  • Patient experienced a stroke within 4 weeks prior to the procedure.
  • History of severe disabling stroke according to the modified Rankin scale > 4.
  • Severe renal failure (serum creatinine > 2.0 mg/dL).
  • Severe peripheral arterial occlusive disease, which might impede a safe introduction of a 9F-sheath for the use of a Mo.Ma-device.
  • Any known allergies and / or intolerances to the following: ASA, Clopidogrel, Statins, Heparin, Nitinol, contrast agents (that cannot be adequately pre-medicated).
  • Patient currently participating in an investigational drug or device study which has not reached the primary endpoint yet or which clinically interferes with the DESERVE study endpoints.
  • Any planned major surgery within 30 days after the study procedure.
  • In the investigators opinion patient has a severe co-morbid condition(s) that could limit the ability to participate in the study.

Angiographic exclusion criteria:

  • Totally occluded internal carotid artery considered as the target vessel.
  • Multiple internal carotid artery stenoses or lesion longer than 4 cm (whichever occurs) that cannot be covered by one (1) stent.
  • Severe ostial stenosis of the common carotid artery.
  • The presence of ipsilateral intracranial stenosis that requires treatment.
  • Contralateral occlusion of the internal carotid arteries associated with a poor collateral flow through the circle of Willis.
  • An aortic arch anatomical complexity that may preclude the safe placement of the Mo.Ma device including particularly, the impossibility to navigate a stiff guide wire into the external carotid artery.

Treatment and study plan

Carotid artery stenting

Device

The MO.MA is a cerebral protection catheter based on the proximal flow blockage concept which is achieved by endovascular clamping of Common Carotid Artery (CCA) and External Carotid Artery (ECA). The MO.MA proximal flow blockage cerebral protection device is indicated to be used in patients eligible for carotid angioplasty and/or the carotid bifurcation and is aimed to prevent brain embolism during the stenting procedure.

For the purpose of this study the Cristallo Ideale™ Carotid Stent System (Invatec S.R.L. Roncadelle, Italy) will be exclusively used. Cristallo Ideale™ consists of a carotid dedicated self-expanding stent pre-mounted on a rapid exchange delivery catheter. The stent platform is made of a Nitinol alloy and characterized by a hybrid design with closed cell in the central zone and open cell in both end zones (proximal and distal).

Primary outcomes

  1. The de-novo occurrence of intra-cerebral lesions per patient by comparing baseline (within 1 week prior procedure) and post-procedural DW-MRI (from 3 to 12 hours post procedure).

    Time frame: 3-12 hours after index procedure

Secondary outcomes

  1. Device Success; Technical Success; Procedural Success; Restenosis rate at 30 days follow up; TLR at 30 days follow up; Access Site Complications; MACCE at 30 days; Incidence of TIA up to 30 days.

    Time frame: 30 days

Sponsors and collaborators

Lead sponsor

Invatec S.p.A.

Industry

Registry information

Official study title

DESERVE: Diffusion Weighted-MRI Based Evaluation of the Effectiveness of Endovascular Clamping During Carotid Artery Stenting With the Mo.Ma Device. A Prospective, Multicenter Study.

Acronym: DESERVE

Important dates

Study start
2008
Primary completion
2010
Study completion
2011
First posted
Nov 26, 2008
Registry last updated
Mar 15, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.